ALL (Acute B-Lymphoblastic Leukemia), Diffuse Large B-cell Lymphoma (DLBCL), High-grade B-cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Refractory Large B-cell Lymphoma, Relapsed Large B-cell Lymphoma, Transformed Follicular Lymphoma (TFL)
Conditions
Keywords
CRC01, anti-CD19 CAR-T, CAR-T, CAR T cells, Chimeric antigen receptor, PD-1 knock down, TIGIT knock down
Brief summary
This is a multi-center, phase I/II study to determine the efficacy and safety of CRC01 in adult patients with relapsed or refractory large B-cell lymphoma and B-cell Acute Lymphoblastic Leukemia.
Interventions
BIOLOGICALCRC01
Cohort A :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 2 x 10\^6 anti-CD19 CAR T cells/kg. Cohort B :A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously at a target dose of 1.5 x 10\^6 anti-CD19 CAR T cells/kg.
DRUGFludarabine
Administered according to package insert
DRUGCyclophosphamide
Administered according to package insert
Sponsors
Curocell Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Cohort A: Inclusion Criteria: 1. ≥ 19 years of age and provided written informed consent 2. Histologically confirmed following large B-cell lymphomas according to the World Health Organization classification 2017 * Diffuse large B-cell lymphoma, not otherwise specified Including Large cell transformation from follicular lymphoma (Transformed follicular lymphoma) * High-grade B-cell lymphoma, not otherwise specified * High-grade B-cell lymphoma with double-hit/triple-hit * Primary mediastinal large B cell lymphoma 3. Relapsed or refractory disease after ≥ two lines of chemotherapy including rituximab, anthracycline and either having failed autologous Hematopoietic stem cell transplantation (ASCT) or being ineligible for or not consenting to ASCT. 4. At least one measurable lesion (Long diameter ≥ 1.5cm) 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 6. Adequate renal and hepatic functions based on the laboratory test results * Total Bilirubin ≤ 2.0mg/dL with the exception of patients with Gilbert-Meulengracht syndrome; patients with Gilbert-Meulengracht syndrome may be included if their total bilirubin is ≤ 3 X ULN and direct bilirubin ≤ 1.5 X ULN. * Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3 X Upper Limit of Normal (ULN) for age with exception of liver metastasis; patients with liver metastasis may be included if their AST and ALT are ≤ 5 X ULN. * Serum creatinine ≤ 1.5 X ULN * Estimated Glomerular Filtration Rate (eGFR) ≥ 60mL/min/1.73m2 7. Adequate hematologic function without transfusions within 2 weeks prior to screening for the study defined as followings: * Hemoglobin \> 8.0g/㎗ * Absolute Neutrophil Count (ANC) \> 1,000/㎕ * Absolute Lymphocyte Count (ALC) ≥ 300/㎕ * Platelets ≥ 50,000/㎕ 8. Must have a minimum level of pulmonary reserve defined as; * ≤ Grade 1 dyspnea per Common terminology criteria for adverse events (CTCAE) v5.0 * pulse oxygenation \> 91% on room air 9. Hemodynamically stable, without pericardial effusion and Left Ventricle Ejection Fraction (LVEF) ≥ 50% confirmed by Echocardiogram (ECG) or Multigated Radionuclide Angiography (MUGA) 10. Must have an apheresis product of non-mobilized cells accepted for manufacturing 11. Life expectancy ≥ 12 weeks 12. Women of child-bearing potential and all male participants must agree to use highly effective methods of contraception for at least 12 months following CRC01 infusion and until CRC01 are no longer present by PCR on two consecutive tests
Exclusion criteria
1. Patients with the following medical history * Previous or concurrent malignancy with the following exceptions: * Adequately treated basal cell or squamous cell carcinoma without evidence of recurrence for at least 3 years prior to the study * In situ carcinoma of the cervix or breast, treated curatively and without evidence of recurrence for at least 3 years prior to the study * A primary malignancy which has been completely resected and in complete remission for ≥ 5 years * Unstable angina and/or myocardial infarction within 12 months prior to screening * Thromboembolic events, pulmonary embolism or bleeding diatheses within 6 months prior to screening * Hypoxemia, significant pleural effusion or significant EKG findings within 6 months prior to the screening 2. Patients with the following concurrent disease at screening: * Central Nervous System (CNS) involvement by malignancy by MRI at screening * Active infection with hepatitis B (HBsAg positive. But, in case of HBcAb IgG positive, the patient can be enrolled in this study if he/she takes prophylactic anti-viral agent.) * Active infection with hepatitis C (HCV RNA positive) * Human immunodeficiency virus (HIV) positive * Active neurological auto-immune or inflammatory disorder (e.g. Guillain Barre Syndrome, Amyotrophic Lateral Sclerosis) * Ventricular tachycardia and atrial fibrillation with rapid ventricular response not controlled with medical treatment within 3 months prior to screening 3. Rapidly progressing the disease as per investigator's discretion 4. Had major surgery requiring general anesthesia or mechanical ventilation within 4 weeks prior to screening (For video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery can be applied with within 2 weeks prior to screening.) 5. Severe infection requiring anti-bacterial, anti-fungal or anti-viral medication or uncontrolled active infection 6. The following treatment history is excluded: * Prior treatment with any prior anti-CD19/anti-CD3 therapy or any other anti-CD19 therapy * Prior treatment with any adoptive T cell therapy * Treatment with any prior gene therapy product * Prior allogeneic HSCT * Patients on oral anticoagulation therapy 7. Eligible for and consenting to ASCT 8. Use of investigational medicinal product/device within 4 weeks prior to screening 9. Pregnant or lactating women 10. Hypersensitivity reaction to the excipients of CRC01 cell product 11. The following treatments are excluded: * Anti-neoplastic therapies including chemotherapy, biologic agents, retinoid therapy, radiotherapy, immune therapy, hormonal therapy, etc. other than lymphodepleting chemotherapy within 2 weeks of leukapheresis and within 2 weeks of CRC01 infusion * Steroids: therapeutic doses of steroids must be stopped \> 7 days prior to leukapheresis and \> 5 days prior to CRC01 infusion. However, the following physiological replacement doses of steroids are allowed: \< 6 mg/m2/day hydrocortisone or equivalent * Immunosuppression: any immunosuppressive medication must be stopped \> 4 weeks prior to leukapheresis and \> 4 weeks prior to CRC01 infusion * Antibody use including anti-CD20 therapy within 4 weeks prior to CRC01 infusion * CNS disease prophylaxis must be stopped \> 1 week prior to CRC01 infusion (e.g. intrathecal methotrexate) Cohort B : Inclusion Criteria : 1. ≥ 19 years of age and provided written informed consent to voluntarily participate in this trial 2. Relapsed or refractory B-cell lymphoblastic leukemia with one of the following: * Primary refractory: Newly diagnosed and refractory to 2 or more cycles of standard chemotherapy * Relapsed within 12 months of the first complete remission * Chemorefractory: Refractory to 1 cycle of chemotherapy conducted after relapse * Relapsed after or refractory to two or more lines of chemotherapy * Relapsed or refractory 100 days after allogeneic HSCT 3. (within 4 weeks prior to screening) Blast of \> 5% identified in the BM 4. (within 4 weeks prior to screening) BM or peripheral blood blast confirmed CD19-positive. Specifically, those with prior treatment with any other anti-CD19 therapy must be confirmed to show CD19 ≥ 90%. 5. Philadelphia chromosome positive with one of the following: * Unable to take tyrosine kinase inhibitors (TKIs) due to side effects * Relapsed or refractory despite treatment with two or more TKIs 6. ECOG performance status of 0-1 7. Confirmed adequate hematologic function defined as follows: * Absolute neutrophil count (ANC) ≥ 500/μL. However, exceptions are made in cases where the Investigator determines that cytopenia is related to the leukemia and may be recovered with leukemia treatment. * Platelet count ≥ 50,000/μL. However, exceptions are made in cases where the Investigator determines that cytopenia is related to the leukemia and may be recovered with leukemia treatment. * Absolute lymphocyte count ≥ 200/μL 8. Adequate renal and hepatic functions confirmed based on the laboratory test results: * Total Bilirubin ≤ 2.0 mg/dL (for patients with Gilbert-Meulengracht syndrome, total bilirubin ≤ 3 × ULN and direct bilirubin ≤ 1.5 × ULN) * AST and ALT ≤ 3 × ULN * Serum creatinine ≤ 1.5 × ULN or eGFR\* ≥ 45 mL/min/1.73 m2 \*MDRD-GFR (mL/min/1.73 m2) = 186 × (serum creatinine)-1.154 × (age)-0.203 (× 0.742 for females) 9. Confirmed to have a minimum level of pulmonary reserve according to the following criteria: * ≤ Grade 1 dyspnea per CTCAE v5.0 * Pulse oxygenation \> 91% on room air 10. Hemodynamically stable, without pericardial effusion, and LVEF ≥ 50% confirmed by ECHO or MUGA scan at Screening 11. Capable of obtaining through leukapheresis non-mobilized cells adequate for CRC01 manufacturing 12. Life expectancy of ≥ 12 weeks 13. Consented to comply with the site visit and test schedules for Primary Follow-up and Secondary Follow-up in accordance with the Protocol for the duration of the Study 14. WOCBP or male subjects who are willing to use appropriate contraceptive methods\* for at least 12 months following CRC01 treatment and until CRC01 is no longer detected through two consecutive PCR tests \* Hormonal contraceptives, placement of intrauterine system, double barrier method (simultaneous use of contraceptive vaginal diaphragm or cervical cap and male condom, along with spermicide), sterilization (vasectomy, bilateral tubal ligation), etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1 Study: Maximum Tolerated Dose (MTD) which will be the Recommended Phase 2 Dose (RP2D) | 28 days | — |
| Phase 2 Pivotal Study: Cohort A : Overall Response Rate (ORR) Cohort B : Overall Complete Remission Rate (OCR) | 5 years | Cohort A : ORR is defined as the incidence of either a complete response (CR) or a partial response (PR) per the Lugano Criteria for Response Assessment (2014). Cohort B : OCR is defined as the incidence of either a complete Remission (CR) or a Complete Remission with incomplete hematologic recovery (CRi) per the ALL Response Criteria. |
Secondary
| Measure | Time frame |
|---|---|
| Time to response (TTR) | 5 years |
| Duration of overall response (DOR) | 5 years |
| Event free survival (EFS) | 5 years |
| Progression free survival (PFS) | 5 years |
| Overall survival (OS) | 5 years |
| Incidence and severity of adverse events (AEs) | 5 years |
| Incidence of immunogenicity to CRC01 | 5 years |
| Number of participants with presence of exposure to replication-competent lentivirus (RCL) as Assessed by quantitative polymerase chain reaction (qPCR) | 5 years |
| Incidence of secondary malignancy | 5 years |
| Peak concentration (Cmax) of CRC01 transduced cells into target tissues | 5 years |
| Area under the concentration versus time curve (AUC) of CRC01 transduced cells into target tissues | 5 years |
| Time to maximum observed concentration (Tmax) of CRC01 transduced cells into target tissues | 5 years |
Countries
South Korea
Contacts
CONTACTBom-I Kwon, BSc
CONTACTGunsoo Kim, MSc
Outcome results
None listed